Skip to content
DataLookout
Menu

SPIBA-101NCT07927972

Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Subcutaneous Injections of Elamipretide in Pediatric Subjects With Barth Syndrome

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 0 → 7 locations
    • Secondary endpoints: 9 to 1
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Maximum plasma concentration of elamipretide and its metabolites
Timeframe: 24 hours
Area under the plasma concentration time curve from 0 to 24 hours
Timeframe: 24 hours

Secondary (1)

Safety Assessments: Adverse Events and Serious Adverse Events

Arms and interventions

ElamipretideExperimental

SC injection daily

Drugs: Elamipretide

Sites

7 sites in 1 country